A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer / Kindler, Hl; Richards, Da; Garbo, Le; Garon, Eb; Stephenson JJ, Jr; Rocha Lima, Cm; Safran, H; Chan, D; Kocs, Dm; Galimi, Francesco; Mcgreivy, J; Bray, Sl; Hei, Y; Feigal, Eg; Loh, E; Fuchs, Cs. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:11(2012), pp. 2834-2842. [10.1093/annonc/mds142]

A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer

GALIMI, Francesco;
2012-01-01

2012
A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer / Kindler, Hl; Richards, Da; Garbo, Le; Garon, Eb; Stephenson JJ, Jr; Rocha Lima, Cm; Safran, H; Chan, D; Kocs, Dm; Galimi, Francesco; Mcgreivy, J; Bray, Sl; Hei, Y; Feigal, Eg; Loh, E; Fuchs, Cs. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 23:11(2012), pp. 2834-2842. [10.1093/annonc/mds142]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11388/46606
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 167
  • ???jsp.display-item.citation.isi??? 155
social impact